An Observational Post-marketing Study for Evaluation of Ongoing Safety and Effectiveness of Catheter Mapping and Ablation Using Commercially Approved Biosense Webster Medical Devices for Cardiac Arrhythmias

What this Trial Is About

Researchers are collecting clinical data to assess the ongoing safety and performance of commercial Biosense Webster Inc. BWI medical devices used during routine cardiac arrhythmia mapping and ablation procedures. The study focuses on patients with cardiac arrhythmias, including atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia. This observational post-marketing study aims to confirm the safety and performance of these devices in real-world settings and expand knowledge about their use in treating arrhythmias. Participants diagnosed with cardiac arrhythmias and scheduled for an ablation procedure will be observed while treated with commercially approved BWI devices such as the BWI therapeutic catheter, Varipulse Catheter, or Dual Energy THERMOCOOL SMARTTOUCH SF Catheter. These devices are used according to routine clinical practice without a specific intervention dictated by the study. Sub-studies include participants treated with the Varipulse Catheter VARIPURE and the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter DUACURE. During the study, participants will be monitored for safety and effectiveness outcomes, including adverse events related to the device or procedure within 7 days and up to 365 days after treatment. Measurements include success rates in isolating targeted pulmonary veins, achieving non-inducibility of tachycardias, freedom from arrhythmia episodes, and rates of repeated ablation. Data collection aligns with standard hospital care and includes follow-up assessments over one year, providing comprehensive information on device performance and patient outcomes.

An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias